- Home
- ACH vs CRBU Comparison
ACH vs CRBU Comparison
Compare ACH & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACH | CRBU |
|---|---|---|
| Founded | 1882 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.3M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACH | CRBU |
|---|---|---|
| Price | $2.41 | $1.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.38 | ★ $10.75 |
| AVG Volume (30 Days) | 822.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.43 | $10.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.66 |
| 52 Week High | $2.80 | $3.53 |
Technical Indicators
Market Signals| Indicator | ACH | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 57.28 |
| Support Level | $1.95 | $1.71 |
| Resistance Level | $2.47 | $2.11 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 58.56 | 50.88 |
Price Performance
Historical ComparisonAbout ACH Accendra Health Inc.
Accendra Health Inc is a world-wide healthcare solutions company providing essential products, services and technology solutions that support care delivery in hospitals, health systems and research centers around the world.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.